NCT00864721COMPLETEDanonymous

Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70

Sponsor

Source record

US Oncology Research

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Sutent

Indication / condition

AI-normalized

Non Small Cell Lung Cancer

Intervention

Source record

Sutent

Related intelligence directories

Indication directory: Non Small Cell Lung Cancer Modality directory: small molecule Target directory: Sutent

Source & freshness

Source record

NCT ID

NCT00864721

Original source

ClinicalTrials.gov

Source last updated

Oct 16, 2018

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00864721

Title

Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70

Sponsor

US Oncology Research

Status

COMPLETED

Phase

PHASE2

Condition raw

Non Small Cell Lung Cancer

Condition normalized

Non Small Cell Lung Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Sutent

Target normalized

Sutent

Interventions

Sutent

Public preview

Source record

The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00864721

Status

COMPLETED

Phase

PHASE2

Sponsor

US Oncology Research

Executive brief

Investment-Ready Snapshot

The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 16, 2018

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00864721

Indication

Non Small Cell Lung Cancer

Modality

small molecule

Target

Sutent

Intervention

Sutent

Source record